There has been considerable interest in the development of novel photosensitisers for photodynamic therapy (PDT). The use of liposomes as drug delivery systems containing simultaneously two or more drugs is an attractive idea to create a new platform for PDT application. Therefore, the aim of this study was to evaluate the synergistic effect of diethyldithiocarbamate (DETC) and zinc phthalocyanine (PDT) co-encapsulated in liposomes. The reverse-phase evaporation method resulted in the successful encapsulation of DETC and ZnPc in liposomes, with encapsulation efficiencies above 85 %, mean size of 308 nm, and zeta potential of ― 36 mV. The co-encapsulation decreased the cytotoxic effects in mouse embryo fibroblast (NIH3T3) cells and inhibited damage to human erythrocytes compared to free DETC + ZnPc. In addition, both the free drugs and co-encapsulated ones promoted more pronounced phototoxic effects on human breast cancer cells (MDA-MB231) compared to treatment with ZnPc alone. This synergistic effect was determined by DETC-induced decreases in the antioxidant enzyme activity of superoxide dismutase (SOD) and glutathione (GSH).

对于用于光动力疗法（PDT）的新型光敏剂的开发已经引起了相当大的兴趣。使用脂质体作为同时包含两种或两种以上药物的药物递送系统，是为PDT应用创建新平台的诱人想法。因此，本研究的目的是评估脂质体中二乙基二硫代氨基甲酸酯（DETC）和酞菁锌（PDT）的协同作用。反相蒸发法成功地将DETC和ZnPc包裹在脂质体内，包裹效率超过85％，平均大小为308 nm，ζ电位为〜36 mV。与游离DETC + ZnPc相比，共包被降低了小鼠胚胎成纤维细胞（NIH3T3）细胞的细胞毒性作用，并抑制了对人红细胞的损害。此外，与单独使用ZnPc的治疗相比，游离药物和共包封的药物对人乳腺癌细胞（MDA-MB231）均具有更明显的光毒性作用。这种协同作用是由DETC诱导的超氧化物歧化酶（SOD）和谷胱甘肽（GSH）的抗氧化酶活性下降所决定的。